Contribution of COVID-19-Related Products to Sales and Profit
First written in FY2021-Q3. 8 of 16 entries say "Advanced", first in FY2021. Latest entry: FY2026.
The whole theme swung hardest in 2019: 2 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Other".
- FY2026Recovery driven by medical devices and LAMP patent royalty incomeAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥7,305 million, up 15.2% year on year, due to a substantial increase in medical device sales and LAMP patent royalty income.」
After the previous period of continued declines in COVID-19 detection reagent sales, the fiscal year ending March 2026 saw the category turn to 15.2% year-on-year growth, driven by higher medical device sales and LAMP patent royalty income. - FY2025Continued decline in sales of COVID-19-related productsAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥6,342 million, down 10.5% year on year, due to substantial declines in medical device sales, COVID-19 detection reagent sales and LAMP patent royalty income.」
After COVID-19 detection reagents and other products had contributed to revenue and earnings, related sales continued to decline 10.5% year on year. - FY2025-H1RestatedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥2,460 million, down 25.1% year on year, due to a decline in sales of COVID-19 detection reagents.」
The contribution of COVID-19 detection reagents to revenue and earnings diminished, resulting in a 25.1% year-on-year decline in revenue from medical devices, genetic testing-related products, etc. - FY2024-Q3RestatedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥5,053 million, down 47.2% year on year, due to a substantial decline in sales of COVID-19 detection reagents.」
The contribution of COVID-19 detection reagents to revenue and earnings diminished, and the decline in revenue from medical devices, genetic testing-related products, etc. continued at 47.2% year on year. - FY2024-Q2RestatedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥3,285 million, down 52.9% year on year, due to a substantial decline in sales of COVID-19 detection reagents.」
After COVID-19-related products had lifted sales of medical devices, genetic testing-related products, etc., sales in the category continued to decline 52.9% year on year due to lower detection reagent sales. - FY2024-Q1Continued decline in sales of COVID-19-related productsAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥1,368 million, down 55.0% year on year, due to a decline in sales of COVID-19 detection reagents.」
The contribution of COVID-19 detection reagents to revenue and earnings diminished, resulting in a 55.0% year-on-year decline in revenue from medical devices, genetic testing-related products, etc. - FY2023Decline in sales of COVID-19-related productsAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥11,716 million, down 1.1% year on year, due to a decline in sales of COVID-19 detection reagents.」
After COVID-19 detection reagents had contributed to revenue and earnings, sales in the Other category declined 1.1% year on year in the current consolidated fiscal year due to the decline in detection reagent sales. - FY2023-Q3AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥9,564 million, up 24.6% year on year, due to sales of COVID-19 detection reagents and a temporary increase in LAMP patent royalty income in the first quarter.」
Sales of COVID-19 detection reagents and a temporary increase in LAMP patent royalty income resulted in revenue from medical devices, genetic testing-related products, etc. of ¥9,564 million, up 24.6% year on year. - FY2023-Q2AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥6,973 million, up 28.3% year on year, due to sales of COVID-19 detection reagents and a temporary increase in LAMP patent royalty income.」
Sales of COVID-19 detection reagents and a temporary increase in LAMP patent royalty income resulted in a 28.3% year-on-year increase in revenue from medical devices, genetic testing-related products, etc. - FY2023-Q1AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥3,042 million, up 18.0% year on year, due to sales of COVID-19 detection reagents, supported by continued testing demand at a certain level reflecting the infection situation in each country, and a temporary increase in LAMP patent royalty income.」
Continued testing demand for COVID-19 detection reagents at a certain level, together with increased LAMP patent royalty income, resulted in an 18.0% year-on-year increase in revenue from medical devices, genetic testing-related products, etc. - FY2022AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥11,842 million, up 20.5% year on year, as demand for COVID-19 detection reagents continued.」
As demand for COVID-19 detection reagents continued, revenue from medical devices, genetic testing-related products, etc. was ¥11,842 million, up 20.5% year on year. - FY2022-Q3AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥7,674 million, up 14.7% year on year, as demand for COVID-19 detection reagents continued. In terms of earnings, profits increased as revenue grew, led by fecal occult blood testing reagents and COVID-19 detection reagents, and operating income was ¥6,643 million, up 20.1% year on year.」
Demand for COVID-19 detection reagents continued, resulting in a 14.7% year-on-year increase in revenue from medical devices, genetic testing-related products, etc., and also contributing to growth in operating income. - FY2022-Q2AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥5,435 million, up 37.4% year on year, due to the substantial increase in sales of COVID-19 detection reagents. In terms of earnings, profits increased as revenue grew, led by fecal occult blood testing reagents and COVID-19 detection reagents, compared with the same period of the previous year, when revenue declined due to interruptions to various health screenings and a decline in the number of outpatients. Operating income was ¥4,831 million, up 77.3% year on year; ordinary income was ¥4,897 million, up 75.2%; and net income attributable to owners of the parent was ¥3,666 million, up 70.4%.」
Due to the substantial increase in sales of COVID-19 detection reagents, revenue from medical devices, genetic testing-related products, etc. increased 37.4% year on year and also contributed to growth in operating income and other earnings. - FY2022-Q1AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥2,578 million, up 44.8% year on year, due to the substantial increase in sales of COVID-19 detection reagents.」
Due to the substantial increase in sales of COVID-19 detection reagents, revenue from medical devices, genetic testing-related products, etc. increased 44.8% year on year. - FY2021AdvancedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥9,827 million, up 76.2% year on year, due to the substantial increase in sales of COVID-19 detection reagents and genetic testing equipment. In terms of earnings, profits increased substantially, led by COVID-19 detection reagents. Operating income was ¥6,612 million, up 43.0% year on year; ordinary income was ¥6,808 million, up 44.1%; and net income attributable to owners of the parent was ¥5,044 million, up 42.5%.」
COVID-19 detection reagents and genetic testing equipment lifted sales of Other products, etc. to ¥9,827 million, up 76.2% year on year, and also contributed to growth in operating income and other earnings. - FY2021-Q3First statedAnnual report
「Revenue for the cumulative third quarter of the current consolidated fiscal year was ¥28,547 million, up 1.9% year on year. Although revenue was affected by interruptions to various health screenings and screening programs and a decline in the number of outpatients due to the spread of COVID-19, sales of COVID-19 detection reagents and genetic testing equipment increased substantially. Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥6,690 million, up 75.3% year on year, due to the substantial increase in sales of COVID-19 detection reagents and genetic testing equipment. In terms of earnings, profits increased substantially, led by COVID-19 detection reagents. Operating income was ¥5,531 million, up 27.2% year on year; ordinary income was ¥5,656 million, up 28.0%; and net income attributable to owners of the parent was ¥4,284 million, up 28.5%.」
Although the Company was affected by interruptions to health screenings and screening programs and a decline in the number of outpatients, the increase in sales of COVID-19 detection reagents and genetic testing equipment lifted total revenue 1.9% year on year and also contributed to growth in operating income and other earnings.